Equity Overview
Price & Market Data
Price: $6.53
Daily Change: -$0.161 / 2.46%
Range: $6.53 - $6.75
Market Cap: $676,084,544
Volume: 1,155,797
Performance Metrics
1 Week: -7.23%
1 Month: 7.75%
3 Months: -17.86%
6 Months: -49.55%
1 Year: -46.81%
YTD: -47.36%
Company Details
Employees: 181
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.